依洛尤单抗对冠心病患者血脂、炎症及血管内皮功能的影响OA
Effect of ilozumab on blood lipid,inflammation and vascular endothelial function in patients with coronary heart disease
目的 观察依洛尤单抗对冠心病患者血脂、炎症及血管内皮功能的影响.方法 抽取2022年1月至2024年1月在该院就诊的110例冠心病患者作为研究对象,开展前瞻性研究,根据计算机随机数字表法,按照进入研究顺序编号,将其分为常规组(55例)和联合组(55例).常规组患者实施经皮冠状动脉介入(PCI)治疗及常规抗血小板治疗,联合组患者采用依洛尤单抗联合PCI治疗.比较2组患者血脂水平、炎症指标、血管内皮功能及治疗安全性.结果 联合组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均低于常规组,高密度脂蛋白胆固醇(HDL-C)水平高于常规组,差异均有统计学意义(P<0.05).联合组患者白细胞介素-6(IL-6)、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、前蛋白转化酶枯草溶菌素9(PCSK9)水平低于常规组,差异均有统计学意义(P<0.05).联合组患者血管紧张素-Ⅱ(Ang-Ⅱ)、内皮素-1(ET-1)、纤溶酶原激活抑制物(PAI-1)、组织型纤溶酶原激活物(t-PA)水平低于常规组,差异均有统计学意义(P<0.05).联合组药物相关不良反应发生率[12.73%(7/55)]与常规组[9.09%(5/55)]比较,差异无统计学意义(P>0.05).结论 依洛尤单抗辅助PCI可在不增加用药风险的同时,有效降低冠心病患者的血脂水平,对减轻患者炎症反应及血管内皮损伤均有积极意义.
Objective To observe the effects of ilozumab on blood lipid,inflammation and vascular en-dothelial function in patients with coronary heart disease.Methods A prospective study was conducted on 110 patients with coronary heart disease who visited the hospital from January 2022 to January 2024.Using a com-puter-generated random number table,110 patients were divided into a conventional group(55 cases)and a combination group(55 cases)according to the order of entry into the study.The conventional group received percutaneous coronary intervention(PCI)treatment and conventional antiplatelet therapy.The combination group was treated with ilozumab combined with PCI.The blood lipid levels,inflammatory indicators,endothe-lial function,and treatment safety of patients were compared between the two groups.Results The levels of total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)in the combination group were lower than those in the combination group,while the level of high-density lipoprotein cholesterol(HDL-C)was higher than that in the conventional group,the differences were all statistically significant(P<0.05).The levels of interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),and prop-rotein convertase subtilisin/kexin 9(PCSK9)in the combination group were lower than those in the conven-tional group,the differences were all statistically significant(P<0.05).The levels of angiotensin Ⅱ(Ang Ⅱ),endothelin-1(ET-1),plasminogen activator inhibitor-1(PAI-1),and tissue type plasminogen activator(t-PA)in the combination group were lower than those in the conventional group,the differences were all statistically significant(P<0.05).The incidence of drug-related adverse reactions in the combination group[12.73%(7/55)]was not statistically different from that in the conventional group[9.09%(5/55)](P>0.05).Conclusion Ilozumab assisted PCI can effectively reduce blood lipid levels in patients with coronary heart disease with-out increasing medication risk,and has a positive effect on reducing inflammation and endothelial damage in patients.
权欢欢;贾鲁姣
平顶山市第二人民医院心血管内二科,河南 平顶山 467000平顶山市第二人民医院心血管内二科,河南 平顶山 467000
医药卫生
冠心病经皮冠状动脉介入依洛尤单抗降脂效果治疗安全性
Coronary heart diseasePercutaneous coronary interventionIlozumabLipid-lower-ing effectTreatment safety
《现代医药卫生》 2026 (4)
751-755,5
评论